Robert Woodrome, MD
Family Medicine · Splendora, TXNPI 1265476998
Payments from drug & device makers
Across 187 payments — averaging $37.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$2K
- AbbVie$1000
- AstraZeneca$883
- GSK$680
- Amgen$251
- Pfizer$244
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,062100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $2,320 |
| AbbVie(2 entities) | 47 | $1,000 |
| AstraZeneca | 11 | $883 |
| GSK | 27 | $680 |
| Amgen | 13 | $251 |
| Pfizer | 10 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $205 |
| Boehringer Ingelheim | 3 | $165 |
| Novo Nordisk | 8 | $159 |
| Otsuka America Pharmaceutical, Inc. | 7 | $120 |
| Sanofi-aventis U.S. LLC | 4 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $102 |
| Mylan Specialty L.p. | 3 | $90 |
| Novartis | 4 | $89 |
| Exact Sciences | 3 | $68 |
| Dexcom, Inc. | 3 | $61 |
| Viatris Specialty LLC | 3 | $59 |
| Lundbeck LLC | 2 | $42 |
| Tactile Systems Technology Inc | 1 | $40 |
| Lilly USA, LLC | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Gilead | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Revance Therapeutics, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Indivior Inc. | 1 | $13 |
| Orexo US, Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,076 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 157 | $157,554 |
| MounjaroTirzepatide | 61 | $70,064 |
| TrulicityDulaglutide | 51 | $61,622 |
| EliquisApixaban | 87 | $60,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $57,235 |
| FarxigaDapagliflozin Propanediol | 65 | $49,943 |
| JardianceEmpagliflozin | 48 | $44,822 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $38,110 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 123 | $33,013 |
| JanuviaSitagliptin Phosphate | 34 | $29,782 |
| XareltoRivaroxaban | 31 | $25,151 |
| EntrestoSacubitril/Valsartan | 19 | $22,313 |
| LinzessLinaclotide | 22 | $15,609 |
| KerendiaFinerenone | 17 | $13,128 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $159 | $169,273168 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $35 | $133,558201 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $883 | $92,820123 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $165 | $60,95971 claims |
| PfizerEliquis | $244 | $60,14587 claims |
| GSKTrelegy Ellipta | $680 | $57,23577 claims |
| NovartisEntresto | $89 | $22,31319 claims |
| AbbVieLinzess | $1,000 | $15,60922 claims |
| Indivior Inc.Suboxone | $13 | $9,21513 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $6,74912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Splendora
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.